Literature DB >> 33213798

Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

Amrit K Kamboj1, David A Katzka1, Prasad G Iyer2.   

Abstract

Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a cancer with increasing incidence and poor survival. Risk of EAC in patients with BE is higher compared with the general population. Endoscopic screening for BE is performed to identify patients earlier in the metaplasia-dysplasia-carcinoma sequence from BE to EAC to enable eradication therapy. BE screening should be considered in individuals with multiple risk factors for BE and EAC. Challenges to BE screening include the absence of a cost-effective, widely applicable minimally invasive screening tool, gastroesophageal reflux disease centric screening recommendations, and limitations of current endoscopic surveillance practice.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barrett’s esophagus; Esophageal adenocarcinoma; Gastroesophageal reflux disease; Screening; Surveillance

Mesh:

Year:  2020        PMID: 33213798      PMCID: PMC8127641          DOI: 10.1016/j.giec.2020.08.002

Source DB:  PubMed          Journal:  Gastrointest Endosc Clin N Am        ISSN: 1052-5157


  107 in total

Review 1.  Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Anamay N Sharma; Mohammad Hassan Murad; Navtej S Buttar; Hashem B El-Serag; David A Katzka; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-22       Impact factor: 11.382

2.  Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study.

Authors:  K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman
Journal:  Gastroenterology       Date:  2013-03-28       Impact factor: 22.682

Review 3.  The Male Predominance in Esophageal Adenocarcinoma.

Authors:  Shao-Hua Xie; Jesper Lagergren
Journal:  Clin Gastroenterol Hepatol       Date:  2015-10-17       Impact factor: 11.382

4.  Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.

Authors:  Neil Gupta; Ajay Bansal; Sachin B Wani; Srinivas Gaddam; Amit Rastogi; Prateek Sharma
Journal:  Gastrointest Endosc       Date:  2011-07-13       Impact factor: 9.427

5.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.

Authors:  A J Cameron; B J Ott; W S Payne
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

6.  Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.

Authors:  Adrian Săftoiu; Cesare Hassan; Miguel Areia; Manoop S Bhutani; Raf Bisschops; Erwan Bories; Irina M Cazacu; Evelien Dekker; Pierre H Deprez; Stephen P Pereira; Carlo Senore; Riccardo Capocaccia; Giulio Antonelli; Jeanin van Hooft; Helmut Messmann; Peter D Siersema; Mario Dinis-Ribeiro; Thierry Ponchon
Journal:  Endoscopy       Date:  2020-02-12       Impact factor: 10.093

7.  Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial.

Authors:  Oliver Old; Paul Moayyedi; Sharon Love; Corran Roberts; Julie Hapeshi; Chris Foy; Clive Stokes; Andrew Briggs; Janusz Jankowski; Hugh Barr
Journal:  J Med Screen       Date:  2015-03-12       Impact factor: 2.136

8.  Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.

Authors:  John M Inadomi; Richard Sampliner; Jesper Lagergren; David Lieberman; A Mark Fendrick; Nimish Vakil
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

Review 9.  Precision prevention of oesophageal adenocarcinoma.

Authors:  Thomas L Vaughan; Rebecca C Fitzgerald
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-10       Impact factor: 46.802

10.  Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.

Authors:  Janusz A Z Jankowski; John de Caestecker; Sharon B Love; Gavin Reilly; Peter Watson; Scott Sanders; Yeng Ang; Danielle Morris; Pradeep Bhandari; Claire Brooks; Stephen Attwood; Rebecca Harrison; Hugh Barr; Paul Moayyedi
Journal:  Lancet       Date:  2018-07-26       Impact factor: 202.731

View more
  3 in total

Review 1.  Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.

Authors:  Sumeet K Mittal; Joe Abdo; Malika P Adrien; Binyam A Bayu; Jay R Kline; Molly M Sullivan; Devendra K Agrawal
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  IL-33 Participates in the Development of Esophageal Adenocarcinoma.

Authors:  Jia Liu; Lei Liu; Yang Su; Yi Wang; Yuchun Zhu; Xiaobin Sun; Yuanbiao Guo; Jing Shan
Journal:  Pathol Oncol Res       Date:  2022-08-30       Impact factor: 2.874

Review 3.  The Use of Confocal Laser Endomicroscopy in Diagnosing Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Jitka Vaculová; Radek Kroupa; Zdeněk Kala; Jiří Dolina; Tomáš Grolich; Jakub Vlažný; David Said; Lydie Izakovičová Hollá; Petra Bořilová Linhartová; Vladimír Procházka; Marek Joukal; Petr Jabandžiev; Ondřej Slabý; Lumír Kunovský
Journal:  Diagnostics (Basel)       Date:  2022-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.